Mission Statement

Our Mission

To bring a highly effective, nontoxic, natural therapy to cancer patients for alleviating the suffering from malignant diseases

To bring more rapid returns on investment than conventional pathways of drug development

Our Objective

Commercialize and distribute the technologies for measuring a newly discovered, highly unique, natural cancer killing activity (CKA) in human granulocytes to the markets of cancer risk management, cancer prevention and cancer treatment for humans

Conduct clinical trials in humans and canines to test a new ground-breaking CKA-based cancer treatment concept, or GIFT, that has shown unprecedented efficacy with minimal side-effect in treating highly aggressive lethal malignancies in preclinical testing

Develop cryo-preservation technologies for long-term storage of human granulocytes that have high CKA for future autologous and allogenic uses